Our study identified Slc22a17 as a potential drug target to design therapies for interventions to enhance neurogenesis in Alzheimer’s disease and proposed additional candidate genes potentially functioning in the NGFR/p75NTR pathway. This evidence concerns the gene SLC22A17 and early-onset autosomal dominant Alzheimer disease.